Cara Therapeutics logo

Cara Therapeutics

Transforming the way pruritus is treated to bring quality to the lives of those who suffer

46 employees · est. 2004 · Stamford, United States

VS
Tricida, Inc. logo

Tricida, Inc.

Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression of CKD.

16 employees · est. 2013 · South San Francisco, United...

Cara Therapeutics is the older company (2004 vs 2013).

Side-by-Side Comparison

Cara Therapeutics Tricida, Inc.
Founded
2004 older 2013
Headquarters
Stamford, United States South San Francisco, United States
Employees
46 16
Industry
Biotechnology, Health Care, Health and Wellness Health Care, Pharmaceutical
Funding Stage
Post Ipo Debt Post Ipo Debt
Total Funding
$517.20M $624.01M
Funding Rounds
10 9
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, Pruritus Treatment, KORSUVA, Difelikefalin, FDA-approved Treatment, Chronic Kidney Disease, Hemodialysis, Oral Formulation, Phase 3 Programs, Non-dialysis Dependent Advanced Chronic Kidney Disease, Atopic Dermatitis, Notalgia Paresthetica, Clinical Trials, Innovation, Medical Research Pharmaceutical Company, Metabolic Acidosis, Chronic Kidney Disease, Drug Candidate, Polymer-based Treatment, Therapeutics Development, CKD Progression, Seasoned Management Team, Therapeutics Commercialization, Polymer Development, Kidney-related Diseases, Veverimer, TRC101, Non-absorbed Drug, Oral Administration
Website
caratherapeutics.com tricida.com
Cara Therapeutics logo

About Cara Therapeutics

Cara Therapeutics, founded in 2004 and headquartered in the United States, is a biopharmaceutical innovator committed to enhancing the treatment of pruritus through novel therapeutic approaches. With its slogan, "Transforming the way pruritus is treated to bring quality to the lives of those who suf...

Tricida, Inc. logo

About Tricida, Inc.

Tricida, Inc. is a pharmaceutical company with a mission to combat metabolic acidosis and the progression of chronic kidney disease (CKD). The company's flagship drug candidate, veverimer (TRC101), is a non-absorbed, orally-administered polymer designed specifically to address metabolic acidosis in...

We will tell you when either one moves

BounceWatch watches Cara Therapeutics and Tricida, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Cara Therapeutics and Tricida, Inc. — by email.

Frequently Asked Questions

Cara Therapeutics — Transforming the way pruritus is treated to bring quality to the lives of those who suffer. Tricida, Inc. — Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression of CKD.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Cara Therapeutics has raised $517.20M while Tricida, Inc. has raised $624.01M.
Cara Therapeutics and Tricida, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Cara Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Cara Therapeutics on 12 Sep 2024, and Tricida, Inc. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy